ZYBAN
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
May 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYBAN is an oral extended-release small-molecule tablet approved in 1997 by GSK for smoking cessation. The drug's mechanism of action and specific indication details are not disclosed in available data, but it represents a non-nicotine pharmacological approach to tobacco dependence treatment. It is administered orally as a tablet formulation.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the brand team is likely focused on lifecycle extension or managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
A 7-year Assessment on Subject Understanding of ZYBAN/ WELLBUTRIN Associated Risks
Started Oct 2016
1 enrolled
Depressive Disorder, Major
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
Started Jun 2003
1,005 enrolled
Smoking Cessation
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
Started May 2003
1,005 enrolled
Smoking Cessation
A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation
Started Feb 2000
625 enrolled
Smoking Cessation
Worked on ZYBAN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.